|
|
||||||||




,
,1
Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Pavillon CHUL, and Faculté de Médecine, Université Laval, Québec, Canada G1V 4G2; and
Pilot Therapeutics Inc., Charleston, South Carolina, USA
1Correspondence: Pilot Therapeutics Inc., 2000 Daniel Island Dr., Suite 440, Charleston, SC 29492, USA. E-mail: MarcS{at}pilott.com
Human group IIA phospholipase A2 (hIIA PLA2) is a 14 kDa secreted enzyme associated with inflammatory diseases. A newly discovered property of hIIA PLA2 is the binding affinity for the heparan sulfate proteoglycan (HSPG) glypican-1. In this study, the binding of hIIA PLA2 to apoptotic human T cells was investigated. Little or no exogenous hIIA PLA2 bound to CD3-activated T cells but significant binding was measured on activated T cells induced to undergo apoptosis by anti-CD95. Binding to early apoptotic T cells was greater than to late apoptotic cells. The addition of heparin and the hydrolysis of HSPG by heparinase III only partially inhibited hIIA PLA2 binding to apoptotic cells, suggesting an interaction with both HSPG and other binding protein(s). Two low molecular weight HSPG were coimmunoprecipitated with hIIA PLA2 from apoptotic T cells, but not from living cells. Treatment of CD95-stimulated T cells with hIIA PLA2 resulted in the release of arachidonic acid but not oleic acid from cells and this release was blocked by heparin and heparinase III. Altogether, these results suggest a role for hIIA PLA2 in the release of arachidonic acid from apoptotic cells through interactions with HSPG and its potential implication in the progression of inflammatory diseases.Boilard, E., Bourgoin, S. G., Bernatchez, C., Poubelle, P. E., Surette, M. E. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans.
Key Words: lymphocytes apoptosis IIA phospholipase A2 heparan sulfate proteoglycan arachidonic acid arthritis
This article has been cited by other articles:
![]() |
A. A. Farooqui, W.-Y. Ong, and L. A. Horrocks Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders Pharmacol. Rev., September 1, 2006; 58(3): 591 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hori, S. J. Spurr-Michaud, C. L. Russo, P. Argueso, and I. K. Gipson Effect of Retinoic Acid on Gene Expression in Human Conjunctival Epithelium: Secretory Phospholipase A2 Mediates Retinoic Acid Induction of MUC16 Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4050 - 4061. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Boilard, S. G. Bourgoin, C. Bernatchez, and M. E. Surette Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2 Blood, October 15, 2003; 102(8): 2901 - 2909. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |